Allogene Therapeutics, Inc. (ALLO)
Allogene Therapeutics, Inc. (ALLO)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Tax benefit at federal statutory rate | NaN | -40,086 | NaN | NaN |
| Research tax credits | NaN | 1,783 | NaN | NaN |
| Change in valuation allowance | NaN | 35,414 | NaN | NaN |
| Stock-based compensation | NaN | 6,280 | NaN | NaN |
| Collaboration revenue - related party | NaN | NaN | 0 | NaN |
| Other | NaN | 175 | NaN | NaN |
| Other adjustments | NaN | 0 | NaN | NaN |
| Income tax expense | NaN | 0 | NaN | NaN |
| Total operating expenses | -120,819 | NaN | 166,911 | NaN |
| Non-cash collaboration revenue - related party | NaN | 0 | 0 | 0 |
| Other income (expenses), net | -11,350 | NaN | 14,835 | NaN |
| Share of loss from equity method investments | NaN | 0 | 0 | 0 |
| Net loss | -42,607 | -38,810 | -41,400 | -110,676 |
| Impairment of long-lived asset | NaN | 0 | 0 | 2,382 |
| Stock-based compensation | 8,270 | 8,130 | 8,652 | 20,860 |
| Depreciation and amortization | 2,869 | 3,057 | 3,097 | 6,205 |
| Impairment of equity investment and equity method investment | NaN | 0 | NaN | NaN |
| Net amortization/accretion on investment securities | 885 | 821 | 923 | 2,477 |
| Non-cash rent expense | 1,069 | 1,047 | 1,031 | 2,277 |
| Deposit placed in escrow | -23,479 | 7 | -12 | 2,711 |
| Prepaid expenses and other current assets | -1,132 | -986 | -1,010 | -1,242 |
| Other long-term assets | -84 | 102 | -315 | 1,503 |
| Accounts payable | 663 | 599 | -1,072 | -758 |
| Accrued and other current liabilities | -5,101 | -118 | 1,086 | -3,488 |
| Operating lease liabilities | -2,202 | -1,889 | -1,855 | -3,759 |
| Other long-term liabilities | 316 | 329 | 359 | 447 |
| Net cash used in operating activities | -12,913 | -27,599 | -29,688 | -91,959 |
| Purchases of property and equipment | 9 | 0 | 243 | 143 |
| Proceeds from sales of investments | NaN | 0 | 0 | NaN |
| Proceeds from maturities of investments | 72,115 | 61,990 | 61,912 | 110,300 |
| Purchase of investments | 101,694 | 28,377 | 49,734 | 60,146 |
| Proceeds from issuance of common stock, net of commissions and issuance of costs-Public Offering | NaN | 0 | 0 | 0 |
| Net cash provided by (used in) investing activities | -29,588 | 33,613 | 11,935 | 50,011 |
| Proceeds from issuance of common stock from atm offering, net of commissions and issuance costs | 20,668 | 7,859 | 2,979 | 11,516 |
| Proceeds from cirm award (note 5) | 0 | 0 | 0 | 6,908 |
| Proceeds from issuance of common stock upon exercise of stock options | 4 | 0 | 0 | 0 |
| Proceeds from issuance of common stock under the employee stock purchase plan | 450 | 0 | 257 | 638 |
| Net cash provided by financing activities | 21,122 | 7,859 | 3,236 | 19,062 |
| Net change in cash and cash equivalents and restricted cash | -21,379 | 13,873 | -14,517 | -22,886 |
| Cash and cash equivalents and restricted cash beginning of period | 61,980 | 48,107 | 85,510 | NaN |
| Cash and cash equivalents and restricted cash end of period | 40,601 | 61,980 | 48,107 | NaN |